Mirati Therapeutics

Cancer is unique. Cancer is smart. Cancer is specific. Treatment should be too. Mirati is at the forefront of precision medicine -- developing genetically-targeted oncology therapeutics for carefully selected groups of patients most likely to benefit from treatment. Mirati’s approach to precision medicine combines three critical factors. Most importantly, Mirati’s drug candidates target specific genetic and epigenetic drivers of cancer. Mirati combines the therapeutic potential of these assets with its creative and agile clinical development strategies focused on identifying and treating patients whose tumors carry the drivers of disease. Finally, this process is led and executed by a highly accomplished precision medicine team, with a track record of bringing breakthrough therapies with accelerated development paths to market.
San Diego, US
Size (employees)
38 (est)
Mirati Therapeutics is headquartered in San Diego, US

Mirati Therapeutics Office Locations

Mirati Therapeutics has an office in San Diego
San Diego, US (HQ)
200 9393 Towne Centre Dr

Mirati Therapeutics Data and Metrics

Mirati Therapeutics Financial Metrics


Net income (FY, 2016)

(83.1 m)

EBIT (FY, 2016)

(83.8 m)

Market capitalization (21-Jul-2017)

118.3 m

Cash (31-Dec-2016)

22.4 m
Mirati Therapeutics's current market capitalization is $118.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

R&D expense

68.5 m

General and administrative expense

15.3 m

Operating expense total

32 m39.1 m64.7 m83.8 m


(32 m)(39.1 m)(64.7 m)(83.8 m)

Pre tax profit

(52.9 m)(43.7 m)(64.5 m)(83.1 m)

Income tax expense

(23 k)

Net Income

(52.9 m)(43.7 m)(64.5 m)(83.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


14.2 m6.6 m49.5 m22.4 m

Current Assets

64.2 m32.7 m125.4 m59.6 m


322 k496 k614 k629 k

Total Assets

64.5 m33.5 m128 m63.4 m

Accounts Payable

15 m

Current Liabilities

38.7 m5.4 m9.8 m15 m

Additional Paid-in Capital

214.8 m260.6 m415.2 m428.5 m

Retained Earnings

(198.4 m)(242.1 m)(306.6 m)(389.8 m)

Total Equity

25.9 m28.1 m118.2 m48.3 m

Financial Leverage

2.5 x1.2 x1.1 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(43.7 m)(64.5 m)(83.1 m)

Depreciation and Amortization

171 k199 k212 k180 k

Cash From Operating Activities

(50.7 m)(68 m)

Purchases of PP&E

(204 k)(386 k)(329 k)(196 k)

Income Taxes Paid

35 k
Y, 2016

Financial Leverage

1.3 x

Mirati Therapeutics Operating Metrics

FY, 2016

Patents Issued


Patents Pending


Mirati Therapeutics Market Value History

Mirati Therapeutics News and Updates

Mirati Therapeutics Company Life and Culture

You may also be interested in